
    
      The primary objective is to evaluate the similarity of clinical efficacy between LY01011 and
      Xgeva® in patients with bone metastases from solid tumors.

      The secondary objective is to evaluate the similarity of clinical safety and immunogenicity
      between LY01011 and Xgeva® in patients with bone metastases from solid tumors.

      Each subject will participate in the study for 53 weeks. Treatments are administered on day 1
      and Q4W thereafter through week 49. All patients are instructed to take 500 mg calcium and
      400 IU vitamin D daily.
    
  